Conditions: Multiple Sclerosis
Keywords: MS
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 39
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine if the study drug is effective and safe in the treatment of Multiple Sclerosis (MS) in patients of Chinese origin.

Detailed description:
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare AG, Germany.

Bayer HealthCare AG, Germany is the sponsor of the trial.

Arms:
arm 1: Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)

Interventions: intervention 1: Interferon beta-1b (Betaseron, BAY86-5046)
Intervention descriptions: intervention 1: Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)

Protocol document: